NCT05889351View on ClinicalTrials.gov

Study to Evaluate the Efficacy, Safety and Tolerability of 3% LTX-109 for Nasal Decolonisation of Staphylococcus Aureus

PHASE2CompletedINTERVENTIONAL
Enrollment

27

Participants

Timeline

Start Date

September 19, 2022

Primary Completion Date

October 28, 2022

Study Completion Date

October 28, 2022

Conditions
Nasal Decolonization of Staphylococcus Aureus
Interventions
DRUG

Vehicle gel, 4 + 4 applications or 4 + 2 applications

Control arm/placebo

DRUG

LTX-109 3% gel, 4 + 4 applications

Cohort 1 active treatment

DRUG

LTX-109 3% gel, 4 + 2 applications

Cohort 2 active treatment

Trial Locations (1)

SE-752 37

ClinSmart Sweden AB, Uppsala

Sponsors

Lead Sponsor

Pharma Holdings AS
All Listed Sponsors
collaborator

CTC Clinical Trial Consultants AB

INDUSTRY

lead

Pharma Holdings AS

INDUSTRY